COMMUNIQUÉS West-GlobeNewswire

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
08/10/2026
CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
08/10/2026
BETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Tilray Brands Delivers Record Q1 Fiscal 2027 Revenue and Record Q1 Gross Profit, Demonstrating the Power of Its Global Platform, Driven by Double-Digit Year-Over-Year Growth Across International Cannabis, Beverage and Pharmaceutical Distribution
08/10/2026
First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record First-Quarter Net Revenue [...]
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
08/10/2026
CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF ), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
HealthTab™ and HeartEye Open New Referral Pathway into Community Pharmacy
08/10/2026
VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) is pleased to announce that its wholly owned subsidiary, HealthTab Ltd. (“HealthTab”), has [...]
NextWave Peptides Builds a Clearer Standard for Research Peptide Information, Documentation, and Fulfillment
08/10/2026
New York, USA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- U.S. Based Research Peptide Company Focuses on Transparent Product Information, Reviewable Documentation, Competitive Pricing, and Direct Customer Support NextWave [...]
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
08/10/2026
Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade to the financial [...]
Regulated information – inside information: Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and confirms FY guidance range
08/10/2026
Regulated information – inside information Nazareth-De Pinte (Belgium)/Rotterdam (The Netherlands), 8 October 2026 – 7:00 AM CET Fagron delivers strong 23.2% revenue growth in the third quarter to €281.3 million and [...]
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
08/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
08/10/2026
October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod [...]
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
08/10/2026
Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p= 0.0176 ) First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac disease argenx [...]
Bio Usawa Takes Major Step Toward Building a Self-Sustaining Biotechnology Ecosystem in Africa
08/10/2026
The establishment of Botswana subsidiary strengthens regional capacity and expands access to affordable biologics SAN FRANCISCO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology today announced the launch of [...]
Neo Dental Beverly Hills Introduces Neo-Essentialism: A Modern Approach to Clinical Decision-Making and a New Way to Think About Dentistry’s Future
08/10/2026
As dentistry moves toward regeneration, artificial intelligence, and biologic preservation, the Beverly Hills dentist behind the concept is asking whether progress may increasingly be defined by what clinicians can [...]
Optogenetic therapy is safe and allows blind people to detect objects
07/10/2026
Five years after a landmark result in one patient, the first treated cohort shows that optogenetic vision restoration works beyond a single case. Basel, 7 October 2026 - An international research team has reported new [...]
Leo International Precision Health AG: Mr. Leo Wang, Disposal
07/10/2026
Leo International Precision Health AG: Mr. Leo Wang, Disposal Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 07. Oct 2026 [...]
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
07/10/2026
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“ [...]
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
07/10/2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the [...]
Lifecore Biomedical to Participate at Upcoming Industry Conferences
07/10/2026
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
07/10/2026
Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin HIGH POINT, N.C., Oct. 07, 2026 (GLOBE NEWSWIRE) -- vTv [...]

Pages